Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
äŒæ¥ã³ãŒãEVAX
äŒç€ŸåEvaxion A/S
äžå Žæ¥Feb 05, 2021
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°46
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Feb 05
æ¬ç€Ÿæåšå°Dr. Neergaards Vej 5F
éœåžHOERSHOLM
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœDenmark
éµäŸ¿çªå·2970
é»è©±çªå·
ãŠã§ããµã€ãhttps://evaxion.ai/
äŒæ¥ã³ãŒãEVAX
äžå Žæ¥Feb 05, 2021
æé«çµå¶è²¬ä»»è
ãCEOã- -
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã